$ARTH
Arch Therapeutics, Inc. Stock $arth

$arth Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000114420414008951 Filed on February 14, 2014

Income Statement

Concept	2013 Q4	2012 Q4
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$520.0K	$160.0K
YoY Change	225.0%
% of Gross Profit
Research & Development	$257.2K	$0.00
YoY Change
% of Gross Profit
Depreciation & Amortization	$0.00	$522.00
YoY Change	-100.0%
% of Gross Profit
Operating Expenses	$780.7K	$162.0K
YoY Change	381.98%
Operating Profit	-$780.7K	-$162.0K
YoY Change	381.98%
Interest Expense	$27.77K	$42.98K
YoY Change	-35.4%
% of Operating Profit
Other Income/Expense, Net	$0.00
YoY Change
Pretax Income	-$810.0K	-$200.0K
YoY Change	305.0%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$808.4K	-$205.0K
YoY Change	294.45%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.01	-$0.04
Diluted Earnings Per Share	-$0.01	-$3.221K
COMMON SHARES
Basic Shares Outstanding	60.15M shares	5.645M shares
Diluted Shares Outstanding	60.15M shares

Balance Sheet

Concept	2013 Q4	2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$950.0K	$0.00
YoY Change		-100.0%
Cash & Equivalents	$945.4K	$9.117K
Short-Term Investments
Other Short-Term Assets	$40.00K	$0.00
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$985.0K	$0.00
YoY Change		-100.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$322.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.06K
YoY Change
Total Long-Term Assets	$10.38K	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$985.0K	$0.00
Total Long-Term Assets	$10.38K	$0.00
Total Assets	$995.4K	$0.00
YoY Change		-100.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$309.6K
YoY Change
Accrued Expenses	$200.0K	$10.00K
YoY Change	1900.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$512.8K	$10.00K
YoY Change	5028.01%
LONG-TERM LIABILITIES
Long-Term Debt	$950.0K	$0.00
YoY Change
Other Long-Term Liabilities	$30.00K
YoY Change
Total Long-Term Liabilities	$972.5K	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$512.8K	$10.00K
Total Long-Term Liabilities	$972.5K	$0.00
Total Liabilities	$1.485M	$10.00K
YoY Change	14752.73%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$60.15K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$489.9K	$0.00
YoY Change
Total Liabilities & Shareholders Equity	$995.4K	$0.00
YoY Change		-100.0%

Cashflow Statement

Concept	2013 Q4	2012 Q4
OPERATING ACTIVITIES
Net Income	-$808.4K	-$205.0K
YoY Change	294.45%
Depreciation, Depletion And Amortization	$0.00	$522.00
YoY Change	-100.0%
Cash From Operating Activities	-$611.9K	-$133.0K
YoY Change	360.01%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.000M	$125.0K
YoY Change	700.0%
NET CHANGE
Cash From Operating Activities	-$611.9K	-$133.0K
Cash From Investing Activities	$0.00	$0.00
Cash From Financing Activities	$1.000M	$125.0K
Net Change In Cash	$388.1K	-$8.022K
YoY Change	-4937.68%
FREE CASH FLOW
Cash From Operating Activities	-$611.9K	-$133.0K
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$611.9K	-$133.0K
YoY Change	360.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Assets Assets	995411	USD
CY2013Q3	us-gaap	Assets Assets	1587332	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	314769	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	187016	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-489862	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1587332	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	995411	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	60145	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	60145	USD
CY2013Q3	us-gaap	Notes Receivable Gross NotesReceivableGross	1000000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	39629	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	985027	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	557319	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	945398	USD
CY2013Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	0	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19629	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	1576948	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	322	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	322	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10062	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10062	USD
CY2013Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	10384	USD
CY2013Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	140840	USD
CY2013Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	203230	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	455609	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	512801	USD
CY2013Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	944707	USD
CY2013Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	947472	USD
CY2013Q3	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	0	USD
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	25000	USD
CY2013Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	944707	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	972472	USD
CY2013Q3	us-gaap	Liabilities Liabilities	1400316	USD
CY2013Q4	us-gaap	Liabilities Liabilities	1485273	USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4758742	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4890305	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	5440312	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5440312	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2880000	USD
CY2013Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	10384	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	309571	USD
CY2013Q3	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	4631871	USD
CY2013Q4	us-gaap	Use Of Estimates UseOfEstimates	<div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; LINE-HEIGHT: normal"> <u><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman','serif'">Use of Estimates</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; LINE-HEIGHT: normal"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman','serif'">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; LINE-HEIGHT: normal"> <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman','serif'"> Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</font></div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60145237	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60145237	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60145237	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60145237	shares
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1735000	USD
CY2013Q4	arth	Convertible Preferred Stock Value Upon Closing Of Preferred Equity Financing ConvertiblePreferredStockValueUponClosingOfPreferredEquityFinancing	1000000	USD
CY2013Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1880000	USD
CY2012Q3	arth	Matured Convertible Notes MaturedConvertibleNotes	1245000	USD
CY2012Q4	arth	Matured Convertible Notes MaturedConvertibleNotes	50000	USD
CY2012Q4	arth	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	1295000	USD
CY2013Q2	arth	Increase In Aggregate Number Of Shares IncreaseInAggregateNumberOfShares	3000000	shares
CY2013Q2	arth	Percentage Of Outstanding Number Of Shares PercentageOfOutstandingNumberOfShares	0.04	pure
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.13	pure
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0280	pure
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0304	pure
CY2013Q4	arth	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate	0.00	pure
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	7011197	shares
CY2013Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	131563	USD
CY2013Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M2D
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3000000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	220000	shares
CY2013Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3220000	shares
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1555000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3220000	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2013Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.20
CY2013Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2013Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.37
CY2013Q4	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	0.37
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.37
CY2013Q4	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedWeightedAverageRemainingContractualTerm	P0Y
CY2013Q4	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm	P0Y
CY2013Q4	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm	P0Y
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y
CY2013Q4	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm	P3Y10M24D
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		USD
CY2013Q4	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedAggregateIntrinsicValue	0	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2013Q4	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodAggregateIntrinsicValue	0	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	27400	USD
CY2013Q4	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue	6850	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	27400	USD
	us-gaap	Revenues Revenues	431461	USD
CY2012Q4	us-gaap	Revenues Revenues	0	USD
CY2013Q4	us-gaap	Revenues Revenues	0	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4185484	USD
CY2012Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	161974	USD
CY2013Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	523443	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1123906	USD
CY2012Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2013Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	257233	USD
	us-gaap	Operating Expenses OperatingExpenses	5309390	USD
CY2012Q4	us-gaap	Operating Expenses OperatingExpenses	161974	USD
CY2013Q4	us-gaap	Operating Expenses OperatingExpenses	780676	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4877929	USD
CY2012Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-161974	USD
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-780676	USD
	us-gaap	Interest Expense InterestExpense	616361	USD
CY2012Q4	us-gaap	Interest Expense InterestExpense	42981	USD
CY2013Q4	us-gaap	Interest Expense InterestExpense	27765	USD
	us-gaap	Other Income OtherIncome	53978	USD
CY2012Q4	us-gaap	Other Income OtherIncome	0	USD
CY2013Q4	us-gaap	Other Income OtherIncome	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-562383	USD
CY2012Q4	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-42981	USD
CY2013Q4	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-27765	USD
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	-204955	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-808441	USD
CY2012Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2013Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2012Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5645212	shares
CY2013Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60145237	shares
CY2013Q3	us-gaap	Notes Payable NotesPayable	944707	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	55293	USD
	us-gaap	Depreciation Depreciation	18371	USD
CY2012Q4	us-gaap	Depreciation Depreciation	522	USD
CY2013Q4	us-gaap	Depreciation Depreciation	0	USD
	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	5753	USD
CY2012Q4	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	0	USD
CY2013Q4	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	419490	USD
CY2012Q4	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
CY2013Q4	us-gaap	Share Based Compensation ShareBasedCompensation	131563	USD
	arth	Noncash Interest Expense On Convertible Notes Payable NoncashInterestExpenseOnConvertibleNotesPayable	469018	USD
CY2012Q4	arth	Noncash Interest Expense On Convertible Notes Payable NoncashInterestExpenseOnConvertibleNotesPayable	33061	USD
CY2013Q4	arth	Noncash Interest Expense On Convertible Notes Payable NoncashInterestExpenseOnConvertibleNotesPayable	27765	USD
	arth	Noncash Interest Expense On Notes Payable To Related Party NoncashInterestExpenseOnNotesPayableToRelatedParty	142057	USD
CY2012Q4	arth	Noncash Interest Expense On Notes Payable To Related Party NoncashInterestExpenseOnNotesPayableToRelatedParty	9241	USD
CY2013Q4	arth	Noncash Interest Expense On Notes Payable To Related Party NoncashInterestExpenseOnNotesPayableToRelatedParty	0	USD
	arth	Issuance Of Common Stock For Services IssuanceOfCommonStockForServices	253	USD
CY2012Q4	arth	Issuance Of Common Stock For Services IssuanceOfCommonStockForServices	0	USD
CY2013Q4	arth	Issuance Of Common Stock For Services IssuanceOfCommonStockForServices	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	39629	USD
CY2012Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-286	USD
CY2013Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	20000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	10062	USD
CY2012Q4	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2013Q4	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	309571	USD
CY2012Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	50832	USD
CY2013Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5198	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	203230	USD
CY2012Q4	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-22009	USD
CY2013Q4	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	62390	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3922260	USD
CY2012Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-133022	USD
CY2013Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-611921	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19054	USD
CY2012Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2013Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19054	USD
CY2012Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2013Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	arth	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	2000000	USD
CY2012Q4	arth	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
CY2013Q4	arth	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
	arth	Proceeds From Repayments Of Notes Payable Related Parties ProceedsFromRepaymentsOfNotesPayableRelatedParties	-373488	USD
CY2012Q4	arth	Proceeds From Repayments Of Notes Payable Related Parties ProceedsFromRepaymentsOfNotesPayableRelatedParties	0	USD
CY2013Q4	arth	Proceeds From Repayments Of Notes Payable Related Parties ProceedsFromRepaymentsOfNotesPayableRelatedParties	0	USD
	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	275200	USD
CY2012Q4	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	0	USD
CY2013Q4	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	0	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	105000	USD
CY2012Q4	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
CY2013Q4	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4886712	USD
CY2012Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	125000	USD
CY2013Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1000000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	945398	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8022	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	388079	USD
CY2006Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17139	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9117	USD
	us-gaap	Interest Paid InterestPaid	98288	USD
CY2012Q4	us-gaap	Interest Paid InterestPaid	0	USD
CY2013Q4	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2012Q4	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013Q4	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	0.27
CY2013Q4	dei	Document Type DocumentType	10-Q
CY2013Q4	dei	Amendment Flag AmendmentFlag	false
CY2013Q4	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2013Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q4	dei	Trading Symbol TradingSymbol	ARTH
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	71545237	shares
CY2013Q4	dei	Entity Registrant Name EntityRegistrantName	Arch Therapeutics, Inc.
CY2013Q4	dei	Entity Central Index Key EntityCentralIndexKey	0001537561
CY2013Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2013Q4	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2012Q4	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	125000	USD
CY2013Q4	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1000000	USD

Files In Submission

Name	View Source	Status
0001144204-14-008951-index-headers.html	Edgar Link	pending
0001144204-14-008951-index.html	Edgar Link	pending
0001144204-14-008951.txt	Edgar Link	pending
0001144204-14-008951-xbrl.zip	Edgar Link	pending
arth-20131231.xml	Edgar Link	completed
arth-20131231.xsd	Edgar Link	pending
arth-20131231_cal.xml	Edgar Link	unprocessable
arth-20131231_def.xml	Edgar Link	unprocessable
arth-20131231_lab.xml	Edgar Link	unprocessable
arth-20131231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v367402_10q.htm	Edgar Link	pending
v367402_ex31-1.htm	Edgar Link	pending
v367402_ex31-2.htm	Edgar Link	pending
v367402_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARTH
Arch Therapeutics, Inc. Stock $arth

2013 Q4 Form 10-Q Financial Statement

#000114420414008951 Filed on February 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH Arch Therapeutics, Inc. Stock $arth

2013 Q4 Form 10-Q Financial Statement

#000114420414008951 Filed on February 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH
Arch Therapeutics, Inc. Stock $arth